Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
Merck
Boehringer Ingelheim
Queensland Health
Fuji
Teva
Express Scripts
Julphar
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,268,847

« Back to Dashboard

Which drugs does patent 8,268,847 protect, and when does it expire?

Patent 8,268,847 protects OPSUMIT and is included in one NDA.

This patent has twenty-seven patent family members in twenty-six countries.
Summary for Patent: 8,268,847
Title:Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Abstract: The invention relates to a product containing the compound of formula (I) below ##STR00001## or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Application Number:12/439,290
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Drugs Protected by US Patent 8,268,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Actelion Pharms Ltd OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,268,847

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2006/052999Aug 29, 2006
PCT/IB2006/053857Oct 19, 2006
PCT Information
PCT FiledAugust 28, 2007PCT Application Number:PCT/IB2007/053448
PCT Publication Date:March 06, 2008PCT Publication Number: WO2008/026156

Non-Orange Book US Patents Family Members for Patent 8,268,847

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,013,210,830 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,268,847

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2009111378 ➤ Subscribe
Portugal 2059246 ➤ Subscribe
New Zealand 575702 ➤ Subscribe
Norway 20091254 ➤ Subscribe
Malaysia 154591 ➤ Subscribe
Mexico 2009002057 ➤ Subscribe
Morocco 30704 ➤ Subscribe
South Korea 101473022 ➤ Subscribe
Japan 5208113 ➤ Subscribe
South Korea 20090057009 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Cipla
Cantor Fitzgerald
Mallinckrodt
Farmers Insurance
Dow
UBS
Fish and Richardson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot